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ABSTRACT
Approximately one half of cancer patients will expe-
rience nausea or vomiting during the course of their
disease either because of the cancer itself or because
of their treatment. Emesis attributable to cancer war-
rants a careful investigation to determine whether a
treatable underlying cause is responsible. Interventions
using dexamethasone and octreotide may reduce vom-
iting attributable to bowel obstruction. In the absence
of a bowel obstruction or a correctable cause, the usual
approach is a sequential trial of antiemetics guided
by considerations of cost and side effects.
Major progress in managing chemotherapy-
induced emesis followed from the use of a combina-
tion of a corticosteroid and 5-hydroxytryptamine3
(5-HT3) receptor antagonist for moderately to highly
emetogenic chemotherapy. Nevertheless, vomiting
still occurred in approximately 40% of women re-
ceiving chemotherapy containing an anthracycline
plus cyclophosphamide and in approximately 50%
of patients receiving high-dose cisplatin. The addi-
tion of aprepitant, a neurokinin 1 receptor antagonist,
improved control of emesis by a further 15%–20%,
and that agent is now recommended as part of stan-
dard antiemetic therapy for patients at high risk of
emesis. Based largely on anecdotal experience, can-
nabinoids and olanzapine are sometimes also recom-
mended in patients with refractory emesis. Phase III
trials are required to confirm their efficacy as add-
ons to a corticosteroid, a 5-HT3 receptor antagonist,
and possibly aprepitant.
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1. INTRODUCTION
Nausea and vomiting are common problems in can-
cer patients throughout the trajectory of their illness.
Whether these patients are receiving high-dose
cisplatin 1 with the best available antiemetic therapy
or are experiencing the advanced stages of cancer 2,
approximately one half will experience nausea or
vomiting, or both. The causes of these distressing
symptoms are diverse, and they include medication,
radiation therapy, and the effect of the cancer itself.
Table I lists some examples. The present article re-
views the approach to emesis attributable to cancer
or chemotherapy.
2. DISCUSSION
Although nausea and vomiting are closely related,
some patients experience one symptom without the
other. For example, mild-to-moderate nausea is often
not accompanied by retching or vomiting. On the
other hand, some patients with brain metastases or
esophageal obstruction report vomiting without prior
nausea.
The physiology of nausea is not well understood 3.
In choosing a pharmacologic approach, no distinc-
tion is usually made between vomiting and nausea;
however, the literature suggests that it is easier to
eliminate vomiting than nausea 4,5.
2.1 Cancer-Induced Emesis
The first step in the approach to cancer-induced eme-
sis is to establish whether a remediable cause is
present. A careful history, physical examination, labo-






TABLE I Causes of nausea and vomiting in the patient with cancer
Chemotherapy
Radiation therapy, especially to upper abdomen
Other medications (for example, opioids)
Cancer
Metabolic effects (for example, hypercalcemia, hyponatremia)
Impaired gastric emptying (for example, ascites)
Gastrointestinal obstruction
Central nervous system metastases (for example, brain)
Others (for example, anxiety, severe pain)WARR
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(Table II). How often a diagnosis can be made of the
underlying cause for emesis is unclear.
A prospective study of 121 patients determined
that 50% were experiencing nausea or vomiting or
both on admission to a hospice 5. The causes were
diagnosed as “chemical” (metabolic, drug-related,
infectious) in 33%, impaired gastric emptying (tu-
mour, hepatomegaly, drug-related, ascites, other) in
44%, visceral or serosal (bowel obstruction, other)
in 31%, intracranial in 8%, and anxiety in 7%. For
each cause, the authors had defined, in advance, a
pharmacologic approach that included one or more
of haloperidol, metoclopramide, cyclizine, dexam-
ethasone, or a benzodiazepine. Indeterminate causes
were treated with levomepromazine.
Although this prospective study reported control
of vomiting in 89% of patients, several problems arise
in applying the results to practise. The criteria for
diagnosing the causes are not listed, and no “gold
standard” exists to determine the accuracy of the di-
agnoses. Of the study patients, 50% were already on
an “appropriate” antiemetic at the time of admission,
raising questions about whether the recommended
pharmacologic approach was actually responsible for
the improvement. After 1 week, 48% of patients had
dropped out of the study. The article also did not state
how often a correctable underlying cause—for ex-
ample, hypercalcemia—was found.
A valid pharmacologic approach to the problem
of nausea and vomiting requires a good evidence base.
Unfortunately, very few controlled trials on this sub-
ject have been conducted. A systematic review of the
efficacy of antiemetics in treating nausea in advanced
cancer was able to find only seven randomized clini-
cal trials: two for bowel obstruction, one for opioid-
related nausea, and three in which several causes
(such as bowel obstruction, brain metastases, meta-
bolic disturbances, and medications) had been ex-
cluded 6. The authors concluded that
• for bowel obstruction, corticosteroids were su-
perior to placebo in one study. (The other study
had a sample size that was inadequate for draw-
ing conclusions.)
• for opioid-related nausea, ondansetron, meto-
clopramide, and placebo are not significantly
different.
• for a non-specific cause for nausea, the 5-hydroxy-
tryptamine3 (5-HT3) receptor antagonist
tropisetron is superior to the more conventionally
prescribed metoclopramide or chlorpromazine.
These conclusions were weakened by small
sample sizes and lack of a double-blind design in
some of the analyzed trials.
The approach to cancer-induced nausea and vom-
iting therefore remains largely empirical:
• When feasible, correct an underlying cause such
as severe hyponatremia.
• In the case of bowel obstruction, use dexametha-
sone 7 or octreotide 8 alone or in combination
(commonly accompanied by a period of “bowel
rest” that relies on hydration by the intravenous
or subcutaneous route) until evidence of obstruc-
tion improves.
For other causes of emesis, empiric trials of
antiemetics (Table III) remain the only source of guid-
ance. Antiemetics are typically chosen based on con-
siderations of past practice, cost, and adverse effects.
Phenothiazines or a butyrophenone, substituted
benzamides, and possibly antihistamines are tried








5-HT3 receptor antagonist Granisetron
Benzodiazepine Lorazepam
NK1 receptor antagonist Aprepitant
5-HT3 = 5-hydroxytryptamine3; NK1 = neurokinin 1.
TABLE II Correctable causes of cancer-related emesis
Cause Specific therapy a




Medication Substitution, discontinuation or reintroduction (in the case of withdrawal reaction) of the responsible drug
Infection Antibiotic therapy
Gastritis Discontinue irritant drug or add a proton pump inhibitor
Bowel obstruction Gastric venting tube, disimpaction
a In most instances, effective treatment of the underlying cancer is helpful as well.
SIADH = syndrome of inappropriate secretion of antidiuretic hormone.NAUSEA AND VOMITING
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before 5-HT3 receptor antagonists or cannabinoids.
The use of aprepitant in this setting has not been
reported.
2.2 Chemotherapy-Induced Nausea and Vomiting
Before the 1980s, chemotherapy-induced vomiting
occurred in a preponderance of patients who received
cisplatin or doxorubicin. In the 1990s, an antiemetic
combination of a corticosteroid and a 5-HT3 receptor
antagonist became common practice for many cyto-
toxic regimens. By the early part of that decade, that
antiemetic combination had had a noticeable impact
on admissions to hospital for control of emesis, lead-
ing to cost savings 9. But despite that progress, sub-
stantial problems with nausea and vomiting remained.
In two large randomized trials, 50% of patients
receiving high-dose cisplatin still experienced vom-
iting and 58% experienced nausea in the face of stan-
dard antiemetic therapy 1. Although traditionally
regarded as “moderately emetogenic,” anthracycline
and cyclophosphamide chemotherapy for breast can-
cer evoked vomiting in 41% of patients and nausea
in 67% following ondansetron and dexamethasone 10.
Those outcomes were vastly better than the outcomes
seen in the 1980s, but considerable room for improve-
ment remained.
Several large comparative studies showed no dif-
ference in efficacy between ondansetron, granisetron,
and dolasetron 11,12. The prevailing belief was that
all 5-HT3 receptor antagonists were equivalent in ef-
ficacy and in side effects when delivered in the rec-
ommended doses. That paradigm was challenged by
palonosetron, an intravenous 5-HT3 receptor antago-
nist with a sufficiently long half life that a single ad-
ministration was sufficient 13.
In patients who received moderately emetogenic
chemotherapy, two large randomized trials showed
superiority for palonosetron over ondansetron 14 and
dolasetron 15. In contrast, palonosetron appeared to
be equivalent to ondansetron in patients who received
high-dose cisplatin 16. Despite those results, the
American Society of Clinical Oncology (ASCO) guide-
lines do not recognize palonosetron as the 5-HT3 re-
ceptor antagonist of choice, because the therapies
used in the study comparator arms were not regarded
as best standard therapy 17. The true role for
palonosetron will be confidently established only by
randomized trials in which the standard therapy con-
forms to recommended practice.
Also in the 1990s, a new of class of antiemetics
was discovered: the neurokinin 1 (NK1) receptor an-
tagonists 18. The NK1 receptor has substance P as its
natural ligand and is present both peripherally and
centrally. Aprepitant is the only example of the NK1
antagonist class that has proceeded through phase III
testing.
Aprepitant is commercially available in many
countries around the world. Its efficacy has been
evaluated in four phase III double-blind randomized
studies—three with high-dose cisplatin 19–21 and one
with chemotherapy containing an anthracycline plus
cyclophosphamide for breast cancer 10. The standard
therapy arms contained ondansetron and dexametha-
sone; in the experimental arm, aprepitant in the cur-
rently approved dose and schedule was added to
ondansetron and dexamethasone. All trials reported
primary endpoints that were statistically significantly
superior in the group receiving aprepitant (Table IV).
A complete response was defined as an absence of
retching or vomiting and no use of an “as-needed”
antiemetic.
The cisplatin studies showed a 14%–20% abso-
lute difference in complete response when aprepitant
was added; in moderately emetogenic chemotherapy,
the difference was only 9%. The apparently lesser
improvement with the addition of an NK1 receptor
antagonist to chemotherapy containing anthracycline
plus cyclophosphamide was further explored by look-
ing at nausea separately from vomiting or retching.
Aprepitant had no detectable effect on nausea attrib-
utable to moderately emetogenic chemotherapy 10, but
a statistically significant improvement was observed
in the pivotal cisplatin studies 1. In contrast, for vom-
iting or retching alone, the superiority in the aprepitant
groups was similar across the phase III studies: a 17%
difference in the moderately emetogenic trial and a
14.3%-to-22.7% difference in the cisplatin trials
(Table IV). Thus, the improved control of vomiting
provided by aprepitant was approximately the same
whether the chemotherapy was high-dose cisplatin
or cyclophosphamide and doxorubicin; however, the
beneficial effect of aprepitant on nausea seemed to
be limited to settings involving high-dose cisplatin.
The reason for the difference is not known.
Because aprepitant is a moderate inhibitor of the
cytochrome P450 enzyme (CYP3A4), concern ini-
tially arose about whether aprepitant might affect the
clearance of taxanes and vinca alkaloids that are
metabolized by that enzyme. Adverse effects in the
aprepitant-containing arms of the phase III trials ap-
peared very similar to those seen in standard therapy,
with no trends across the studies even though patients
commonly received concomitant taxanes, vinorel-
bine, or etoposide 1,10. Subsequent pharmacokinetic
studies that showed no effect of aprepitant on the
clearance of docetaxel 22 or vinorelbine 23 were con-
sistent with the foregoing observations.
Although no interaction with intravenous medi-
cations has thus far been demonstrated, aprepitant
may have clinically relevant interactions with oral
agents that have an extensive first-pass metabolism
connected with CYP3A4 in the bowel wall. For ex-
ample, dexamethasone is metabolized by CYP3A4,
and co-administration with aprepitant results in a
doubling of the area under the curve of the cortico-
steroid 24. For that reason, the phase III clinical trials
were designed to deliver approximately one half theWARR
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dose of dexamethasone in the group that received
aprepitant. Aprepitant would also be expected to tem-
porarily increase the blood levels of other oral agents
metabolized by CYP3A4—as do ketoconazole, eryth-
romycin, diltiazem, and a number of other commonly
prescribed medications. Through induction of en-
zymes, aprepitant reduces warfarin levels by approxi-
mately one third 25, and the aprepitant product
monograph indicates that aprepitant may reduce the
efficacy of the birth control pill. Because aprepitant
itself is metabolized by CYP3A4, strong inducers of
that enzyme such as rifampin and phenytoin may
lower blood levels of the drug sufficiently to make it
ineffective.
Aprepitant is an oral medication. It supplied as a
3-day pack: 125 mg on day 1, and 80 mg on each of
days 2 and 3. Approval is being sought for a single
intravenous dose of a prodrug that yields an area
under the curve similar to that seen with oral
aprepitant.
Standard antiemetic therapy recommended by
ASCO 17 and the Multinational Association for Sup-
portive Care in Cancer 26 now includes aprepitant for
chemotherapy with cisplatin and with anthracycline
plus cyclophosphamide. Still, several questions re-
main about aprepitant use:
• What should be done for patients taking other
emetogenic chemotherapy such as carboplatin or
ifosfamide?
• What should the aprepitant dosing schedule be
for multiple-day cisplatin?
• Does aprepitant have a role as a second-line
antiemetic?
Aprepitant is an important step forward, but some
patients still vomit or experience substantial nausea
despite its use. In addition, aprepitant is not avail-
able in some countries, and like the 5-HT3 receptor
antagonists, it is relatively expensive and may there-
fore not be an option for some patients. Other agents
that might be added include a dopamine receptor an-
tagonist (for example, prochlorperazine), a cannab-
inoid (nabilone or dronabinol), and the atypical
antipsychotic olanzapine. Prochlorperazine appears
to have very modest effects on chemotherapy-induced
nausea and vomiting 27. Cannabinoids have some
anecdotal support, but the data from clinical trials
antedate the introduction of 5-HT3 receptor antago-
nists, and in recommended doses, significant prob-
lems with sedation and dysphoria arise. Olanzapine
blocks multiple receptors, including dopamine recep-
tors 28. Anecdotal accounts and phase II studies sug-
gest an important antiemetic effect 29,30, but phase III
data are not yet available.
Tables V and VI outline a reasonable approach to
antiemetic therapy that is consistent with the avail-
able evidence.
3. SUMMARY
Cancer-related nausea results from a wide variety of
causes, some of which cannot be clearly established
by any investigation. Although therapy that aims to
correct the underlying cause is rational, for many
patients, such an approach is not possible. Few ran-
domized trials have been conducted in this setting,
and the sample sizes in the trials that have been con-
ducted are small. The use of a corticosteroid or
octreotide for bowel obstruction is supported by ran-
domized trials. The 5-HT3 receptor antagonists have
not been established to be efficacious for nausea re-
sulting from opioid administration, but they may be
helpful for nausea of uncertain origin in patients with
advanced cancer. Given the limited data from clini-
cal trials, a sequential pharmacologic approach based
largely on past practise and considerations of costs
and adverse effects is reasonable.
Chemotherapy-related nausea and vomiting re-
mains a problem in many patients despite the use of
5-HT3 receptor antagonists and dexamethasone. As
an add-on to standard therapy, the NK1 receptor an-
tagonist aprepitant reduces the likelihood of vomit-
ing or retching in association with cisplatin or
anthracycline-plus-cyclophosphamide chemotherapy
by an absolute 15%–20%. Add-on aprepitant is rec-
ommended as first-line therapy by several prominent
guidelines groups. Olanzapine and cannabinoids have
been suggested as potentially useful interventions,
but data from phase III clinical trials are lacking.
TABLE IV Phase III results with aprepitant
Reference Patients (n) Chemotherapy type Result
Hesketh et al., 2003 19 520 Cisplatin Superior CR with aprepitant (72.7% vs. 52.3%, p<0.01);
> 70 mg/m2 22.7% difference in no-vomiting rate.
Poli-Bigelli et al., 2003 20 523 Cisplatin Superior CR with aprepitant (62.7% vs. 43.3%, p<0.001);
> 70 mg/m2 22% difference in no-vomiting rate.
Warr et al., 2005 10 857 Anthracycline plus Superior CR with aprepitant (50.8% vs. 42.5%, p=0.015);
cyclophosphamide 17% difference in no vomiting rate.
Schmoll et al., 2006 21 489 Cisplatin Superior CR with aprepitant (72% vs. 61%, p=0.003);
> 70 mg/m2 14.3% difference in no-vomiting rate.
CR = complete response (defined as no vomiting or retching, and no use of “as needed” antiemetics from hour 0 to hour 120).NAUSEA AND VOMITING
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